Across TCGA pan-cancer cohorts, KCTD16 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated KCTD16 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher KCTD16 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated KCTD16 expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

PDAC and GBM are the cancer types where KCTD16 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.587	0.226	.012	8	view →
GBM	DFS	Median	All	0.829	0.667	.013	4	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: KCTD16 tumor-vs-normal RNA expression · all KCTD16 data types